Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julien Hadoux

Showing results (101-110 of 116) with videos related to

Pageof 12
Sort By:
European Journal of Cancer (Oxford, England : 1990)|June 5, 2021
Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d'Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN networkJulien Hadoux, Christina Kanaan, Alice Durand, et al.
Pediatric Blood & Cancer|March 16, 2026
European Standard Clinical Practice Guideline and EXPeRT Recommendations for the Diagnosis and Management of Gastroenteropancreatic Neuroendocrine Neoplasms in Children and AdolescentsMichaela Kuhlen, Calogero Virgone, Antje Redlich, et al.
The New England Journal of Medicine|October 23, 2023
Phase 3 Trial of Selpercatinib in Advanced <i>RET</i>-Mutant Medullary Thyroid CancerJulien Hadoux, Rossella Elisei, Marcia S Brose, et al.
Thyroid : Official Journal of the American Thyroid Association|November 27, 2023
Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW StudyVivek Subbiah, Mimi I Hu, Aaron S Mansfield, et al.
Thyroid : Official Journal of the American Thyroid Association|October 19, 2023
Factors Associated with Survival in Anaplastic Thyroid Carcinoma: A Multicenter Study from the ENDOCAN-TUTHYREF NetworkArnaud Jannin, Fabiola Giudici, Christelle de la Fouchardière, et al.
The Journal of Clinical Endocrinology and Metabolism|March 30, 2021
Recurrence-Free Survival Analysis in Locally Advanced Pheochromocytoma: First AppraisalSophie Moog, Frédéric Castinetti, Christine DoCao, et al.
Nature Cancer|February 5, 2022
Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohortLaurence Albiges, Stéphanie Foulon, Arnaud Bayle, et al.
The Lancet. Oncology|June 1, 2026
[<sup>177</sup>Lu]Lu-dota-tate versus sunitinib in patients with metastatic progressive neuroendocrine tumours of the pancreas (OCLURANDOM): a randomised, controlled, phase 2 trialEric Baudin, Alice Durand, Amandine Beron, et al.
The Journal of Clinical Endocrinology and Metabolism|January 31, 2019
Positive Impact of Genetic Test on the Management and Outcome of Patients With Paraganglioma and/or PheochromocytomaAlexandre Buffet, Laurène Ben Aim, Sophie Leboulleux, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 14, 2026
Impact of the French ENDOCAN-COMETE Network on Overall Survival in Rare Adrenocortical CarcinomasRossella Libé, Matthieu Faron, Anne-Sophie Foucan, et al.
Pageof 12

Showing results (101-110 of 116) with videos related to

Sort By:
Pageof 12
European Journal of Cancer (Oxford, England : 1990)|June 5, 2021
Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d'Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN networkJulien Hadoux, Christina Kanaan, Alice Durand, et al.
Pediatric Blood & Cancer|March 16, 2026
European Standard Clinical Practice Guideline and EXPeRT Recommendations for the Diagnosis and Management of Gastroenteropancreatic Neuroendocrine Neoplasms in Children and AdolescentsMichaela Kuhlen, Calogero Virgone, Antje Redlich, et al.
The New England Journal of Medicine|October 23, 2023
Phase 3 Trial of Selpercatinib in Advanced <i>RET</i>-Mutant Medullary Thyroid CancerJulien Hadoux, Rossella Elisei, Marcia S Brose, et al.
Thyroid : Official Journal of the American Thyroid Association|November 27, 2023
Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW StudyVivek Subbiah, Mimi I Hu, Aaron S Mansfield, et al.
Thyroid : Official Journal of the American Thyroid Association|October 19, 2023
Factors Associated with Survival in Anaplastic Thyroid Carcinoma: A Multicenter Study from the ENDOCAN-TUTHYREF NetworkArnaud Jannin, Fabiola Giudici, Christelle de la Fouchardière, et al.
The Journal of Clinical Endocrinology and Metabolism|March 30, 2021
Recurrence-Free Survival Analysis in Locally Advanced Pheochromocytoma: First AppraisalSophie Moog, Frédéric Castinetti, Christine DoCao, et al.
Nature Cancer|February 5, 2022
Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohortLaurence Albiges, Stéphanie Foulon, Arnaud Bayle, et al.
The Lancet. Oncology|June 1, 2026
[<sup>177</sup>Lu]Lu-dota-tate versus sunitinib in patients with metastatic progressive neuroendocrine tumours of the pancreas (OCLURANDOM): a randomised, controlled, phase 2 trialEric Baudin, Alice Durand, Amandine Beron, et al.
The Journal of Clinical Endocrinology and Metabolism|January 31, 2019
Positive Impact of Genetic Test on the Management and Outcome of Patients With Paraganglioma and/or PheochromocytomaAlexandre Buffet, Laurène Ben Aim, Sophie Leboulleux, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 14, 2026
Impact of the French ENDOCAN-COMETE Network on Overall Survival in Rare Adrenocortical CarcinomasRossella Libé, Matthieu Faron, Anne-Sophie Foucan, et al.
Pageof 12